Quxiang Li

Title: Quxiang Li: Innovator in Pharmaceutical Development

Introduction

Quxiang Li is a notable inventor based in Xuzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating various mental health disorders. His work is characterized by a focus on innovative solutions that address the needs of patients suffering from schizophrenia and Parkinson's disease.

Latest Patents

Quxiang Li holds a patent for a compound titled "1,5-Dihydro-2,4-Benzodiazepine-3-One Derivative And Application Thereof." This compound acts on 5-HT2A and 5-HT2C receptors, demonstrating selectivity for 5-HT2A that is superior or similar to that of pimavanserin. The derivative is designed for treating schizophrenia, Parkinson's disease, dementia-related behavioral disorders, and psychosis. Notably, the antipsychotic activity of this compound is comparable to that of pimavanserin, while exhibiting fewer side effects, such as sedation and worsening of exercise, as well as reduced cardiotoxicity.

Career Highlights

Quxiang Li is currently employed at Jiangsu Nhwa Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has been instrumental in creating effective treatments that improve the quality of life for patients with serious mental health conditions.

Collaborations

Some of his coworkers include Xiangqing Xu and Yinli Qiu, who contribute to the collaborative environment at Jiangsu Nhwa Pharmaceutical Co., Ltd. Their combined expertise fosters innovation and drives the development of new therapeutic solutions.

Conclusion

Quxiang Li's contributions to pharmaceutical innovation highlight his commitment to improving mental health treatment options. His work exemplifies the impact of dedicated research and development in the field of medicine.